Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins.

Background: Although clinicians avoid giving meropenem to patients with penicillin allergy because of potential cross-reactivity, the rate of cross-reactivity between penicillins and meropenem has not been prospectively determined.

Objective: To assess the tolerability of meropenem in patients with documented penicillin allergy.

Design: Prospective skin testing and antibiotic challenge.

Setting: Allergy units of 2 Italian medical centers.

Patients: 104 consecutive participants with immediate hypersensitivity reactions to penicillins and positive skin test results to at least 1 penicillin reagent.

Measurements: Skin tests to meropenem and, if results were negative, challenges with escalating doses of meropenem.

Results: One participant (0.9% [95% CI, 0.02% to 5.2%]) had a positive intradermal test result to meropenem. The remaining 103 participants with negative skin test results to meropenem tolerated escalating dose challenges.

Limitation: Challenges were not followed by therapeutic courses.

Conclusions: These data indicate a low rate of cross-reactivity between penicillins and meropenem. Therefore, the practice of avoiding meropenem therapy in penicillin-allergic patients should be reconsidered. In patients who especially require meropenem treatment, the authors recommend pretreatment skin tests because negative results indicate tolerability.